Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer

Stopped The study was terminated because we were not able to obtain the study drug.

Conditions

• Metastatic Melanoma
• Metastatic Renal Cancer

Interventions

• DRUG: Zanolimumab
• DRUG: Aldesleukin

Sponsor

National Cancer Institute (NCI)